Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038082 | 1.00 | CYP1A2 (0.40) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL18555576 | 0.88 | CYP1A2 (0.39) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL18555574 | 0.88 | CYP1A2 (0.39) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL18555601 | 0.88 | CYP1A2 (0.39) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL23070651 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL30480051 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL28621956 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL23070666 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL29977880 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 | |
| SCHEMBL29977249 | 0.87 | NTRK1 (0.45) | CYP1A2POLBCYP3A4CYP2C19ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CYP1A2 4751/4885POLB 3283/4885CYP3A4 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.